New'Reference Regimen' in Metastatic Pancreatic Cancer? New'Reference Regimen' in Metastatic Pancreatic Cancer?
Liposomal irinotecan plus chemo in the new NALIRIFOX regimen significantly improved overall survival compared with standard therapy in metastatic pancreatic ductal adenocarcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 23, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
A Guide to Managing Gastric Intestinal Metaplasia A Guide to Managing Gastric Intestinal Metaplasia
Most patients won ' t develop adenocarcinoma or require continued surveillance, but identifying those who might requires a bit more effort, says Dr David Johnson.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 20, 2023 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news
My Risk Revealed: A Confirmed BRCA2 Mutation
(MedPage Today) -- Cancer is a part of my family story. My grandmother on my father's side died of pancreatic adenocarcinoma in her early 70s, when I was a young teenager. My grandfather and uncle died of esophageal cancer in their early 50s. So... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 30, 2022 Category: Hematology Source Type: news
Mum's 'stomach bug' is found to be stage three rectal adenocarcinoma: Cancer in Australia
A single mum who thought she had a dreadful 'tummy bug' was instead diagnosed with bowel cancer after visiting her doctor. (Source: the Mail online | Health)
Source: the Mail online | Health - October 28, 2022 Category: Consumer Health News Source Type: news
Recognizing Intersectionality Can Heal America's Health
(MedPage Today) -- As a 66-year-old African-American gentleman with rectal bleeding and abdominal pain, George was terrified. His workup had revealed a colonic mass with biopsy-confirmed colorectal adenocarcinoma.
Thankfully, George's cancer was... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 17, 2022 Category: American Health Source Type: news
The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET | Science Signaling
The kinase PLK1 fuels lung cancer growth by amplifying tumorigenic MAPK signaling. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 4, 2022 Category: Science Source Type: news
Mayo Clinic Researchers ID Potential Gene Marker for Treating Pancreatic Cancer
ROCHESTER, Minn. — Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to a more effective, precision treatment for pancreatic ductal adenocarcinoma (PDAC). The researcher’s findings are published in Nature Cancer. “Pancreatic ductal adenocarcinoma is one of t he most lethal cancers,” says the paper’s senior author Zhenkun Lou, Ph.D. Dr. Lou says while Poly-ADP-ribose-polymerase inhibitors (PARPi) are now an FDA-approved option for standard maintenance therapy for patients with metastatic PDAC who harbor pathogenic… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - September 22, 2022 Category: Research Source Type: news
FDG-PET May Predict Response to Neoadjuvant Therapy in Pancreatic Cancer
THURSDAY, Sept. 15, 2022 -- For patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal adenocarcinoma (PDAC), preoperative fluorodeoxyglucose positron emission tomography (FDG-PET) may predict pathologic response to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 15, 2022 Category: Pharmaceuticals Source Type: news
Epstein-Barr Virus Linked With Gastric Cancer
(MedPage Today) -- A substantial proportion of gastric cancers worldwide was linked with the Epstein-Barr virus (EBV), according to a meta-analysis.
In a pooled analysis involving over 68,000 patients with conventional gastric adenocarcinoma in... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 12, 2022 Category: Gastroenterology Source Type: news
Radiomics-Based AI Models Can Detect PDAC From Prediagnostic CT
WEDNESDAY, Aug. 10, 2022 -- Radiomics-based machine learning (ML) models can detect pancreatic ductal adenocarcinoma (PDAC) from prediagnostic computed tomography (CT) images, according to a study published online June 30 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 10, 2022 Category: Pharmaceuticals Source Type: news
Neoadjuvant mFOLFIRINOX Studied for Borderline Resectable PDAC
WEDNESDAY, Aug. 3, 2022 -- For patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC), favorable overall survival was observed following treatment with eight cycles of neoadjuvant modified FOLFIRINOX (mFOLFIRINOX), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 3, 2022 Category: Pharmaceuticals Source Type: news
Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Surveillance of High-Risk Group May Downstage Pancreatic Cancer
WEDNESDAY, July 20, 2022 -- Surveillance of high-risk individuals may downstage pancreatic ductal adenocarcinoma (PDAC), according to a study published online June 15 in the Journal of Clinical Oncology.
Mohamad Dbouk, M.D., from the Sol Goldman... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2022 Category: Pharmaceuticals Source Type: news
Chemo-Free Maintenance Combo Promising in Pancreatic Cancer
(MedPage Today) -- Pairing a PARP inhibitor and immune checkpoint inhibitor together may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma (PDAC), according to findings of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 12, 2022 Category: Hematology Source Type: news
Adding Opdivo in First-Line Shows Promise in HER2+ Esophagogastric Cancer
(MedPage Today) -- A combination of the PD-1 inhibitor nivolumab (Opdivo) plus trastuzumab and chemotherapy (mFOLFOX6) was effective as first-line therapy for patients with HER2 (ERBB2)-positive esophagogastric adenocarcinoma, according to results... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 23, 2022 Category: Hematology Source Type: news
